Comparison
GHRP-6 vs Nicotinamide Riboside
Side-by-side of GHRP-6 and Nicotinamide Riboside. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
GHRP-6
First-generation hexapeptide ghrelin-receptor agonist. Pioneered the GHS-R1a pathway in the 1980s. Produces the strongest hunger response among GHRPs and a mo.
Nicotinamide Riboside
Nicotinamide riboside (NR) is the most-studied NAD+ precursor in humans. Sold as Niagen by Chromadex; raises plasma NAD+ 30-60% at 250-1,000 mg/day.
Effects at a glance
GHRP-6
- •First-generation hexapeptide ghrelin-receptor agonist; foundational to the GHRP class
- •Strongest appetite stimulation of any synthetic GHRP at equivalent GH doses
- •Produces measurable cortisol and prolactin rise alongside the GH pulse
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Largely superseded by ipamorelin (cleaner profile) and GHRP-2 (stronger pulse) for body-composition use
- •Banned by WADA under S2; detection methods validated in accredited labs
Nicotinamide Riboside
- •Most-studied NAD+ precursor in human trials; the original Niagen formulation by Chromadex
- •Plasma NAD+ rises 30-60% at 250-1,000 mg/day across multiple human PK trials
- •Martens 2018 reported reduced BP and arterial stiffness at 500 mg/day for 6 weeks
- •Dollerup 2018 found no insulin sensitivity change despite plasma NAD+ rise
- •Tissue NAD+ rise inconsistent; hard clinical endpoints not yet measured
- •Larger human safety database than NMN; comparable mechanistic effects
Side-by-side
| Attribute | GHRP-6 | Nicotinamide Riboside |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Growth Hormone Releasing Peptide 6, SKF-110679, Histidyl-D-Tryptophyl-Alanyl-Tryptophyl-D-Phenylalanyl-Lysinamide | NR, Niagen, nicotinamide riboside chloride |
| Half-life (hr) ↗ | 0.5 | 8 |
| Typical dose (mg) ↗ | 0.1 | 500 |
| Dosing frequency | 2-3x daily | daily, typically morning |
| Routes | subcutaneous, intravenous | oral |
| Onset (hr) | 0.25 | 1 |
| Peak (hr) | 0.5 | 4 |
| Molecular weight | 872.44 | 255.25 |
| Molecular formula | C46H56N12O6 | C11H15N2O5 |
| Mechanism | Hexapeptide agonist of GHS-R1a (ghrelin receptor). Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs, with strong central NPY/AgRP appetite signaling and modest cortisol and prolactin release. | NAD+ precursor via salvage pathway. Phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+. Substrate for sirtuins, PARPs, and CD38. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | OTC dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled (research chemical) | OTC supplement |
| Pregnancy | Insufficient data; not recommended | Insufficient data at supplement doses |
| CAS | 87616-84-0 | 1341-23-7 |
| PubChem CID | 9919072 | 439924 |
| Wikidata | Q5519921 | Q3343054 |
Safety profile
GHRP-6
Common side effects
- intense hunger
- water retention
- vivid dreams
- head pressure or flushing
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin sensitivity
Interactions
- CJC-1295: synergistic GH release; commonly co-administered(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Nicotinamide Riboside
Common side effects
- mild GI upset (rare)
- headache (rare)
Contraindications
- pregnancy / lactation (insufficient data)
- active cancer (theoretical, no contraindicating data)
Interactions
- pterostilbene: complementary sirtuin pathway (Basis combination)(minor)
- TMG (trimethylglycine): methylation support during high NAD+ precursor dosing(minor)
Which Should You Take?
Nicotinamide Riboside comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. GHRP-6 is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick GHRP-6.
- → If your priority is appetite regulation, pick GHRP-6.
- → If your priority is healthspan extension, pick Nicotinamide Riboside.
- → If your priority is energy and stamina, pick Nicotinamide Riboside.
Edge case: If you want to avoid research-only / gray-market sourcing, Nicotinamide Riboside is the more accessible choice.
Default choice: Nicotinamide Riboside. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for GHRP-6 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between GHRP-6 and Nicotinamide Riboside?
GHRP-6 and Nicotinamide Riboside differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, GHRP-6 or Nicotinamide Riboside?
GHRP-6 half-life is 0.5 hours; Nicotinamide Riboside half-life is 8 hours.
Can you stack GHRP-6 with Nicotinamide Riboside?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper